Taken together, these findings explain the biological mechanisms through which galectin-1, galectin-9, and alpha-1-microglobulin are related to cardiovascular disease progression, and therefore, may act as prognostic biomarkers for MACE in patients with PAD. This evidence concerns the gene LGALS9 and peripheral arterial disease.